X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs WYETH LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD WYETH LTD ORCHID PHARMA LTD/
WYETH LTD
 
P/E (TTM) x -0.7 27.7 - View Chart
P/BV x 0.5 5.3 9.2% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ORCHID PHARMA LTD   WYETH LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
WYETH LTD
Mar-13
ORCHID PHARMA LTD/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1941,044 18.6%   
Low Rs35818 4.3%   
Sales per share (Unadj.) Rs276.5298.6 92.6%  
Earnings per share (Unadj.) Rs-79.257.2 -138.4%  
Cash flow per share (Unadj.) Rs-43.558.4 -74.4%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs53.9249.5 21.6%  
Shares outstanding (eoy) m70.4522.72 310.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.1 13.3%   
Avg P/E ratio x-1.416.3 -8.9%  
P/CF ratio (eoy) x-2.615.9 -16.5%  
Price / Book Value ratio x2.13.7 56.9%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m8,06721,157 38.1%   
No. of employees `0002.80.5 569.1%   
Total wages/salary Rs m2,527400 631.8%   
Avg. sales/employee Rs Th6,956.113,787.4 50.5%   
Avg. wages/employee Rs Th902.5813.0 111.0%   
Avg. net profit/employee Rs Th-1,993.02,643.3 -75.4%   
INCOME DATA
Net Sales Rs m19,4776,783 287.1%  
Other income Rs m407353 115.5%   
Total revenues Rs m19,8847,136 278.6%   
Gross profit Rs m1,1031,617 68.2%  
Depreciation Rs m2,51927 9,470.7%   
Interest Rs m5,2276 95,032.7%   
Profit before tax Rs m-6,2361,938 -321.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-5 -10,019.6%   
Tax Rs m-125632 -19.8%   
Profit after tax Rs m-5,5801,301 -429.1%  
Gross profit margin %5.723.8 23.7%  
Effective tax rate %2.032.6 6.2%   
Net profit margin %-28.719.2 -149.4%  
BALANCE SHEET DATA
Current assets Rs m11,0146,984 157.7%   
Current liabilities Rs m32,0602,056 1,559.4%   
Net working cap to sales %-108.172.6 -148.7%  
Current ratio x0.33.4 10.1%  
Inventory Days Days9599 95.6%  
Debtors Days Days3424 140.2%  
Net fixed assets Rs m29,440244 12,050.7%   
Share capital Rs m705227 310.1%   
"Free" reserves Rs m2,0435,441 37.5%   
Net worth Rs m3,8005,668 67.0%   
Long term debt Rs m9,01825 36,071.6%   
Total assets Rs m46,5107,901 588.7%  
Interest coverage x-0.2353.3 -0.1%   
Debt to equity ratio x2.40 53,805.1%  
Sales to assets ratio x0.40.9 48.8%   
Return on assets %-0.816.5 -4.6%  
Return on equity %-146.922.9 -640.0%  
Return on capital %-3.734.0 -11.0%  
Exports to sales %37.90.2 17,361.2%   
Imports to sales %22.636.3 62.2%   
Exports (fob) Rs m7,37815 49,848.6%   
Imports (cif) Rs m4,4062,465 178.7%   
Fx inflow Rs m7,51315 49,429.6%   
Fx outflow Rs m5,6492,677 211.0%   
Net fx Rs m1,865-2,662 -70.0%   
CASH FLOW
From Operations Rs m1,682923 182.2%  
From Investments Rs m-9,860317 -3,111.5%  
From Financial Activity Rs m6,644-481 -1,381.2%  
Net Cashflow Rs m-1,535759 -202.2%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 7.2 45.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 30.4 181.9%  
Shareholders   84,811 21,978 385.9%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   BIOCON LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jan 16, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - SHASUN PHARMA COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS